FibroGen Inc (FGEN)
0.304
-0.02
(-5.68%)
USD |
NASDAQ |
Nov 05, 16:00
0.304
0.00 (0.00%)
After-Hours: 18:51
FibroGen Net Income (Quarterly): -15.54M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -15.54M |
| March 31, 2024 | -32.93M |
| December 31, 2023 | -56.23M |
| September 30, 2023 | -63.62M |
| June 30, 2023 | -87.68M |
| March 31, 2023 | -76.70M |
| December 31, 2022 | -66.18M |
| September 30, 2022 | -91.65M |
| June 30, 2022 | -72.62M |
| March 31, 2022 | -63.20M |
| December 31, 2021 | -134.08M |
| September 30, 2021 | 49.80M |
| June 30, 2021 | -133.99M |
| March 31, 2021 | -71.76M |
| December 31, 2020 | -58.63M |
| September 30, 2020 | 33.00M |
| June 30, 2020 | -85.31M |
| March 31, 2020 | -78.35M |
| December 31, 2019 | -98.12M |
| September 30, 2019 | -49.44M |
| June 30, 2019 | 116.00M |
| March 31, 2019 | -45.41M |
| Date | Value |
|---|---|
| December 31, 2018 | 20.95M |
| September 30, 2018 | -42.56M |
| June 30, 2018 | -23.42M |
| March 31, 2018 | -41.40M |
| December 31, 2017 | -33.89M |
| September 30, 2017 | -24.46M |
| June 30, 2017 | -31.91M |
| March 31, 2017 | -30.61M |
| December 31, 2016 | -30.39M |
| September 30, 2016 | -24.15M |
| June 30, 2016 | 24.32M |
| March 31, 2016 | -27.84M |
| December 31, 2015 | -51.37M |
| September 30, 2015 | -45.10M |
| June 30, 2015 | 57.06M |
| March 31, 2015 | -46.37M |
| December 31, 2014 | -50.56M |
| September 30, 2014 | -39.54M |
| June 30, 2014 | 46.83M |
| March 31, 2014 | -16.24M |
| December 31, 2013 | -26.77M |
| September 30, 2013 | 39.30M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-134.08M
Minimum
Dec 2021
49.80M
Maximum
Sep 2021
-63.36M
Average
-71.76M
Median
Mar 2021
Net Income (Quarterly) Benchmarks
| Merck & Co Inc | 3.157B |
| Biomarin Pharmaceutical Inc | 106.08M |
| Arbutus Biopharma Corp | -19.80M |
| GlycoMimetics Inc | -10.10M |
| Cidara Therapeutics Inc | -91.21M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 50.64M |
| Total Expenses (Quarterly) | 61.56M |
| EPS Diluted (Quarterly) | -0.16 |
| Enterprise Value | 6.090M |
| Gross Profit Margin (Quarterly) | 89.78% |
| Profit Margin (Quarterly) | -30.69% |
| Earnings Yield | -562.5% |
| Normalized Earnings Yield | -529.16 |